Molecular Classification of Refractory Anemia: A Comprehensive Review

Abstract

Refractory anemia (RA) represents a challenging hematologic disorder within the myelodysplastic syndromes (MDS), characterized by persistent anemia unresponsive to standard therapies. Advances in molecular diagnostics have enabled the stratification of RA based on distinct genetic and epigenetic alterations, offering refined prognostication and guiding targeted management. This review synthesizes recent evidence on the molecular classification of RA, emphasizing its epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic algorithms, and the implications of molecular findings for treatment, with a focus on integrating guideline recommendations and emerging therapeutic strategies for improved patient outcomes.

Introduction

Refractory anemia is a subtype of myelodysplastic syndromes marked by chronic, non-iron-deficiency anemia and bone marrow dysplasia. The evolution of molecular biology has transformed the understanding and clinical approach to RA, allowing for classification based on specific gene mutations and cytogenetic profiles. This molecular paradigm shift is reshaping diagnostic and therapeutic pathways, underscoring the importance of tailored management in improving prognosis and quality of life for affected patients.

Epidemiology / Disease Burden

RA predominantly affects elderly populations, with a median age at diagnosis of approximately 70 years. Men are slightly more affected than women. Incidence rates vary globally, ranging from 3 to 5 cases per 100,000 annually, but are rising due to population aging and improved diagnostic recognition. RA comprises a significant proportion of lower-risk MDS cases but remains a major contributor to morbidity, transfusion dependence, and progression to acute myeloid leukemia (AML). Healthcare burden is amplified by frequent hospitalizations, need for chronic transfusion support, and iron overload complications.

Pathophysiology

The pathogenesis of RA involves ineffective erythropoiesis due to clonal expansion of hematopoietic stem cells with acquired genetic and epigenetic lesions. Key molecular drivers include mutations in genes such as SF3B1, TET2, ASXL1, SRSF2, and DNMT3A. These mutations disrupt splicing, DNA methylation, chromatin remodeling, and apoptosis, leading to impaired erythroid differentiation and increased marrow dysplasia. SF3B1 mutations, in particular, are linked with ring sideroblast formation and more favorable prognosis. Chromosomal abnormalities, such as del(5q), further refine subclassification and risk stratification. Recent multi-omics studies highlight additional layers of complexity involving microRNA dysregulation and aberrant signaling pathways.

Risk Factors

Established risk factors for RA include advanced age, prior exposure to cytotoxic agents or radiation, inherited bone marrow failure syndromes, and environmental toxins such as benzene. Genetic predisposition, though less common, may play a role in familial cases. Clonal hematopoiesis of indeterminate potential (CHIP) can precede overt MDS and RA, particularly in older adults. Lifestyle factors such as smoking and chronic inflammation may also contribute to disease onset and progression by promoting genomic instability within hematopoietic progenitor cells.

Clinical Features

RA typically presents insidiously with symptoms of chronic anemia, including fatigue, pallor, dyspnea, and reduced exercise tolerance. Physical examination may reveal pallor and, in transfusion-dependent patients, signs of iron overload such as hepatosplenomegaly. Laboratory findings include persistent normocytic or macrocytic anemia unresponsive to conventional therapies, reticulocytopenia, and dysplastic erythroid precursors on peripheral smear. Bone marrow biopsy remains central, demonstrating erythroid hyperplasia, megaloblastic changes, and often ring sideroblasts. Cytopenias in other lineages may be present but are not predominant.

Diagnosis

The diagnostic approach to RA integrates clinical evaluation, laboratory findings, and comprehensive marrow analysis. Exclusion of secondary causes of anemia, such as nutritional deficiencies and chronic inflammatory states, is essential. Bone marrow examination identifies dysplasia in ≥10% of erythroid precursors, with or without ring sideroblasts. Cytogenetic analysis provides critical prognostic information, while next-generation sequencing (NGS) for somatic mutations refines classification and may guide therapy. Ancillary studies, including flow cytometry and iron studies, further delineate the diagnosis. Integration of molecular data into the Revised International Prognostic Scoring System (IPSS-R) enhances risk assessment.

Treatment & Management

Management of RA is tailored according to risk stratification, transfusion dependency, and molecular profile. Supportive care remains foundational, comprising red blood cell transfusions and iron chelation in patients with chronic transfusion requirements. Erythropoiesis-stimulating agents (ESAs) are first-line for patients with low endogenous erythropoietin levels and lower-risk disease. Immunosuppressive therapy may benefit selected patients, especially those with hypoplastic marrow or specific HLA types. Lenalidomide is indicated for RA with isolated del(5q) cytogenetic abnormality. Hypomethylating agents (azacitidine, decitabine) are reserved for higher-risk or ESA-refractory cases. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative option but is limited by age, comorbidities, and donor availability.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the molecular landscape of RA, leading to the development of novel targeted therapies. Luspatercept, a TGF-β superfamily ligand trap, has demonstrated efficacy in improving erythroid response and reducing transfusion burden, particularly in patients with SF3B1 mutations and ring sideroblasts. Spliceosome modulators and agents targeting specific molecular defects are under clinical investigation. NGS-driven identification of actionable mutations enables enrollment in precision medicine trials. Gene-editing approaches and chimeric antigen receptor (CAR) T-cell therapies, though early in development, represent promising future directions. Integration of molecular classification into clinical practice is refining trial design and therapeutic decision-making.

Guideline Recommendations

International guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN) advocate for comprehensive molecular and cytogenetic workup in RA. Risk-adapted management strategies are emphasized, including early initiation of ESAs, judicious use of transfusions, iron chelation therapy, and consideration of lenalidomide in del(5q) RA. Hypomethylating agents are recommended for higher-risk or refractory cases. Molecular findings should inform prognosis and eligibility for novel agents or clinical trials. Regular monitoring of disease progression, iron overload, and therapy-related complications is critical for optimizing outcomes.

Conclusion

The molecular classification of refractory anemia has redefined the diagnostic and therapeutic landscape of this complex disorder. Integration of genetic, epigenetic, and cytogenetic data enables precise risk stratification, individualized treatment, and improved patient outcomes. Ongoing research into disease mechanisms and targeted therapies holds promise for further advances, underscoring the importance of molecularly informed clinical practice in the management of RA.